Outcomes monitoring in pulmonary endarterectomy: Paving the road to success | Revista Portuguesa de Cardiologia (English edition)
Advanced Search
Share
COVID-19
Metrics
Editorial Board
Publish in this journal
  • Instructions for authors
  • Submit an article
  • Ethics in publishing
  • Editorial statute
Share
October 2021 Outcomes monitoring in pulmonary endarterectomy: Paving the road to success
    Revista Portuguesa de Cardiologia (English edition)
    ISSN: 2174-2049

    The Portuguese Journal of Cardiology, the official journal of the Portuguese Society of Cardiology, was founded in 1982 with the aim of keeping Portuguese cardiologists informed through the publication of scientific articles on areas such as arrhythmology and electrophysiology, cardiovascular surgery, intensive care, coronary artery disease, cardiovascular imaging, hypertension, heart failure and cardiovascular prevention. The Journal is a monthly publication with high standards of quality in terms of scientific content and production. Since 1999 it has been published in English as well as Portuguese, which has widened its readership abroad. It is distributed to all members of the Portuguese Societies of Cardiology, Internal Medicine, Pneumology and Cardiothoracic Surgery, as well as to leading non-Portuguese cardiologists and to virtually all cardiology societies worldwide. It has been referred in Medline since 1987.

    See more

    Indexed in:

    Index Medicus/Medline, Science Citation Index Expanded/Journal of Citation Reports, Scopus

    See more

    Follow us:

    Impact factor

    The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

    © Clarivate Analytics, Journal Citation Reports 2021

    See more
    Impact factor 2020
    1.374
    Citescore

    CiteScore measures average citations received per document published.

    See more
    Citescore 2019
    1.4
    SJR

    SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

    See more
    SJR 2019
    0.23
    SNIP

    SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

    See more
    SNIP 2019
    0.423
    View more metrics
    Open Access Option
    Hide
    Journal Information
    Previous article | Next article
    Vol. 40. Issue 10.
    Pages 753-755 (October 2021)
    Share
    Share
    Print
    Download PDF
    More article options
    ePub
    Statistics
    Vol. 40. Issue 10.
    Pages 753-755 (October 2021)
    Editorial comment
    DOI: 10.1016/j.repce.2021.10.006
    Open Access
    Outcomes monitoring in pulmonary endarterectomy: Paving the road to success
    Monitorização de resultados em endarterectomia pulmonar. Construindo o caminho para o sucesso
    Visits
    ...
    Download PDF
    Maria José Loureiro
    Cardiologist, Pulmonary hypertension specialist
    This item has received
    ...
    Visits
    (Daily data update)

    Under a Creative Commons license
    Article information
    Full Text
    Bibliography
    Download PDF
    Statistics
    Full Text

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of clinical and subclinical pulmonary embolism, characterized by unresolved fibro-thrombotic obstructions of the pulmonary arteries in combination with a secondary microvasculopathy of small vessels. Pulmonary endarterectomy (PEA) offers the best chance of symptomatic and prognostic improvement and is therefore the treatment of choice for the disease. Percutaneous balloon pulmonary angioplasty (BPA) and medical therapy have a potential role in patients unsuitable for PEA or with residual disease after surgery.

    In this issue of the Portuguese Journal of Cardiology, Plácido et al.1 describe the clinical and surgical outcomes of 27 consecutive CTEPH patients who underwent PEA at an international surgical center, discuss pre and post-PEA management strategy, and conclude advocating for comparable assessment of outcomes at the recently-designated Portuguese PEA center.

    First, it is important to highlight that all patients were diagnosed and medically managed in one national pulmonary hypertension (PH) referral center,2 thus potentially being offered full diagnostic investigation, an accurate PH differential diagnosis and state-of-the-art CTEPH management. Second, and despite reporting on a contemporary cohort of patients (2015-2019), both the mean time from symptom onset to diagnosis (3.3 years) and from diagnosis to surgery (2.6 years) are undesirably high. Not surprisingly, near to 90% of this population was in advanced functional class, more than half needed long-term oxygen therapy and 93% were on specific pulmonary vasodilator therapy before surgery. Although not associated with operability in the International CTEPH registry, longer diagnostic and treatment delays adversely impact disease morbidity and mortality.3–5 This can be presumably attributed to the development of a secondary microvasculopathy downstream of non-occluded pulmonary arteries and underscores the need for timely diagnosis and surgical treatment of CTEPH.

    Pulmonary endarterectomy should be offered to all eligible patients with operable CTEPH. Appropriate assessment of operability is key to ensure that patients who have technically accessible disease are not misclassified and denied the benefits of PEA, and that patients who are ineligible due to comorbidities and/or would not benefit from surgery are correctly identified. However, as mentioned by Plácido et al., operability assessment is complex, cannot easily be standardized and depends on the experience of the surgeon. In view of this, the 2015 European Society of Cardiology/European Respiratory Society (ERS) Guidelines for the diagnosis and treatment of pulmonary hypertension,6 the 6th World Symposium on Pulmonary Hypertension proceedings7 and the ERS Statement on Chronic Thromboembolic Pulmonary Hypertension,8 all recommend that endarterectomy feasibility and patient eligibility should be discussed within a multidisciplinary team that includes an experienced PEA surgeon, a PH specialist, a BPA interventionist and a CTEPH-trained radiologist. When a patient is considered inoperable in specific settings (e.g., emerging sites, low-volume sites, participation in clinical trials), re-evaluation of operability by a second experienced center is recommended, so that patients with operable CTEPH are robustly identified. Remarkably, the authors report that 27 out of 29 consecutive patients were deemed operable and eligible, while registry data suggest that near a third of patients diagnosed with CTEPH did not proceed to PEA surgery in the past.3 The reported high operability rate is probably in line with the redefinition of the distal limits of endarterectomy as a result of advances in imaging techniques and surgical technique refinement in the high-volume experienced center where PEA was undertaken (Papworth Hospital in Cambridge is the national center for PEA in the United Kingdom).

    All patients who underwent surgical treatment showed substantial improvement in clinical and invasive haemodynamic profile post-PEA. The benefit persisted for most patients in a median follow-up of 34 months, even though 56% of patients presented some degree of residual pulmonary hypertension after surgery. Importantly, and aligned with these positive surgical outcomes, 26% of patients were withdrawn from specific pulmonary vasodilator therapy and 48% weaned from oxygen therapy. Perioperative complications occurred in one fifth of the patients. However, no significant post-operative permanent morbidity or mortality were reported in this series. These surgical outcomes are consistent with prior reports from the International CTEPH registry and several other series.3,4,9

    Even though there is no definition of successful outcome after PEA, CTEPH patients would expect to survive the operation without major morbidity and gain improved functional capacity and quality of life that is sustained to prolong lifetime. Experts have suggested that a successful outcome after PEA presumes in-hospital mortality <5% and three year survival of 90%, as well as improved functional class and quality of life.8 The benchmarks of postoperative mortality and three year survival were set by the International CTEPH registry published in 20119 and the New International CTEPH registry published in 2016.4

    Similar to many other cardiac and thoracic surgical indications, PEA surgical outcomes are closely related to patient selection, waiting time from acceptance to surgery, meticulous surgical technique, and high-quality perioperative care. Experts from leading surgical centers have proposed a definition of expert surgical center which factors surgical mortality (30-day or in-hospital mortality <5%), ability to perform distal segmental-level endarterectomy and ability to offer all three modalities of treatment (PEA, BPA and medical therapy). Based on mortality data in small, intermediate, and large volume centers participating in the International CTEPH registry,9 it is also the experts view that PEA should only be performed at selected centers with a case volume of >50 procedures per year.7,10 Regarding surgical volume, one could argue that high surgical volume may not be attainable for smaller countries like Portugal, considering the low incidence of CTEPH. Furthermore, other small countries have reported single-center outcomes similar to high-volume international centers.11,12 It is important to note that for most centers, a learning curve effect has been clearly demonstrated, with higher in-hospital mortality and procedural complication rates being reported in the early phase of the learning curve, followed by a reduction in in-hospital mortality with increasing experience. Currently, and for a starting PEA program, clinical practice suggests systematic mentoring and specialized skills training for one year and experience of at least 50 procedures in a high-volume center, with the aim of aiding new PEA surgeons to negotiate the steep learning curve and achieve good outcomes.8

    For nearly two decades, Portuguese CTEPH patients have been referred to different international PEA centers for surgery under a national health service sponsored program (Mobilidade Internacional de Doentes Portal da Mobilidade dos Doentes (dgs.pt)).13 The Royal Papworth Hospital in the UK, the Marie Lannelongue Hospital in France, the Kerckhoff Clinic Bad Nauheim in Germany and the Hospital Universitario 12 de Octubre in Spain are among the healthcare institutions that have operated on eligible CTEPH patients. Plácido et al.1 report for the first time on a cohort of 27 Portuguese patients undergoing PEA in the sole UK center offering PEA. Having performed more than 2000 operations since 1996, and carrying out 170-190 PEA operations per year, the Royal Papworth Hospital reports some of the best outcomes internationally.

    Recently, the national health authorities designated a national reference center for PEA.2 It is of relevance, and at the current stage of the national PEA program, patients undergo risk stratification followed by triage, in order to identify complex cases who could benefit from PEA surgery in an international high-volume center. A national PEA center can potentially improve accessibility and reduce cost, among other indisputable advantages. Overcoming the administrative burden caused by complexities of referral abroad and the lengthy approval process may reduce time on the waiting list and allow for timely surgery. Accessibility could also improve in those cases when fear of out-of-pocket expenses, lack of information and apprehension about the process, as well as insufficient linguistic fluency in a foreign language negatively impact the decision of a patient to be referred for surgery abroad. If equivalent outcomes are achieved one can also argue that the total cost for hospitalization, surgery, physician fees, air transportation, and hotel expenses abroad are far more likely to be more than the cost of the procedure in a national center. Nevertheless, cost reduction might be hindered by the cost of long-term PH-specific medical therapies in patients that present significant residual disease.

    Whether a national reference center for PEA can produce equivalent outcomes in the same risk category population requires careful assessment. Measurement and monitoring of outcomes is essential to ensure that the performance of the national PEA program is aligned with its intent and that resources are used efficiently and effectively.14 This assessment will also provide data to stakeholders and decision makers on the benefits of national versus outsourced CTEPH surgical care abroad. While the importance of assessing any surgical program outcomes is clear, the methodology of doing so is far more intricate. Validated metrics and high-quality data are crucial to rigorous decision making. Yet only recently a national PH registry was put in place that will allow data collection and characterization of the clinical course and outcomes of surgical and nonsurgical therapies for patients with CTEPH in the future.

    The primary concern of physicians and patients considering CTEPH treatment strategies is the quality of care and patient outcomes. A PEA expert center offers optimal CTEPH assessment and treatment by a multidisciplinary team comprised of medical, surgical, and interventional physicians with relevant expertise in CTEPH. For the future, a major task will be to tailor the optimal treatment strategy to the individual CTEPH patient, but also to decide where it should be offered.

    Conflicts of interest

    The author has no conflicts of interest to declare.

    References
    [1]
    Plácido and colleagues – ref RPC.
    [2]
    Centros de Tratamento de Hipertensão Arterial Pulmonar e de Tromboendarterectomia Pulmonar. Direção-Geral da Saúde (dgs.pt) [accessed 01.07.21]
    [3]
    J. Pepke-Zaba, M. Delcroix, I. Lang, et al.
    Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.
    Circulation, 124 (2011), pp. 1973-1981
    http://dx.doi.org/10.1161/CIRCULATIONAHA.110.015008 | Medline
    [4]
    M. Delcroix, I. Lang, J. Pepke-Zaba, et al.
    Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry.
    Circulation, 133 (2016), pp. 859-871
    http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016522 | Medline
    [5]
    F.A. Klok, S. Barco, S.V. Konstantinides, et al.
    Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry.
    Eur Respir J, 52 (2018), pp. 1801687
    http://dx.doi.org/10.1183/13993003.01687-2018 | Medline
    [6]
    N. Galiè, M. Humbert, J.L. Vachiery, et al.
    2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) International Society for Heart and Lung Transplantation (ISHLT).
    Eur Respir J, 46 (2015), pp. 903-975
    http://dx.doi.org/10.1183/13993003.01032-2015 | Medline
    [7]
    N.H. Kim, M. Delcroix, X. Jais, et al.
    Chronic thromboembolic pulmonary hypertension.
    Eur Respir J, 53 (2019), pp. 1801915
    http://dx.doi.org/10.1183/13993003.01915-2018 | Medline
    [8]
    M. Delcroix, A. Torbicki, D. Gopalan, et al.
    ERS statement on chronic thromboembolic pulmonary hypertension.
    Eur Respir J, 57 (2021), pp. 2002828
    http://dx.doi.org/10.1183/13993003.02828-2020 | Medline
    [9]
    E. Mayer, D. Jenkins, J. Lindner, et al.
    Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry.
    J Thorac Cardiovasc Surg, 141 (2011), pp. 702-710
    http://dx.doi.org/10.1016/j.jtcvs.2010.11.024 | Medline
    [10]
    D. Jenkins, M. Madani, E. Fadel, et al.
    Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension.
    Eur Respir Rev, 26 (2017), pp. 160111
    http://dx.doi.org/10.1183/16000617.0111-2016 | Medline
    [11]
    K. Korsholm, A. Andersen, S. Mellemkjær, et al.
    Results from more than 20-years of surgical pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension in Denmark.
    Eur J Cardiothorac Surg, 52 (2017), pp. 704-709
    http://dx.doi.org/10.1093/ejcts/ezx182 | Medline
    [12]
    J. Kallonen, N. Glaser, F. Bredin, et al.
    Life expectancy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Swedish single-center study.
    Pulm Circ, 10 (2020),
    http://dx.doi.org/10.1177/2045894020918520 | Medline
    [13]
    (Mobilidade Internacional de Doentes Portal da Mobilidade dos Doentes (dgs.pt)) [accessed 01.07.21]
    [14]
    J. Fragata, H. Telles.
    Pulmonary thromboendarterectomy in Portugal: initial experience.
    Rev Port Cardiol (Engl Ed), 39 (2020), pp. 505-512
    Copyright © 2021. Sociedade Portuguesa de Cardiologia


    Subscribe to our newsletter

    Special content about COVID-19
    • Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit
    • Facemasks during aerobic exercise: Implications for cardiac rehabilitation programs during the Covid-19 pandemic
    • Sinus Node Syndrome in a critical COVID-19 patient
    • Diagnosis of Takotsubo syndrome in the COVID-19 era
    See more
    Tools
    • Print
    • Send to a friend
    • Export reference
    • CrossMark
    • Mendeley
    • Statistics
    Recommended
    articles
    Chronic thromboembolic pulmonary hypertension: Initial...
    Rev Port Cardiol. 2021;40:741-52
    Balloon pulmonary angioplasty protocol in a Portuguese...
    Rev Port Cardiol. 2021;40:653-65
    Safety and efficacy of balloon pulmonary angioplasty in a...
    Rev Port Cardiol. 2021;40:739-40
    Sociedade Portuguesa de Cardiologia
    Publish in
    Revista Portuguesa de Cardiologia
    • Instructions for authors
    • Submit an article
    • Ethics in publishing
    • Editorial statute
    Revista Portuguesa de Cardiologia (English edition) is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
    www.publicationethics.org.

    Read

    • Articles in press
    • Current Issue
    • Most Often Read

    Archive

    • Archive

    Publish in this journal

    • Instructions for authors
    • Submit an article
    • Ethics in publishing
    • Editorial statute
    • Editorial Board

    Legal terms

    • Reproduction terms
    • Terms and conditions
    • Privacy policy

    Subscribe

    • Email alerts
    • RSS
    Contact
    Editorial Board
    © Copyright 2022. Sociedade Portuguesa de Cardiologia

    Cookies are used by this site. To decline or learn more, visit our Cookies page.
    Elsevier España S.L.U. © 2022. Todos los derechos reservados
    Idiomas
    • English
    • Português
    Revista Portuguesa de Cardiologia (English edition)
    • Current Issue
    • Articles in press
    • Archive
    • Most Often Read
    • Open Access
    • Editorial Board
    • Publish in this journal
      • Instructions for authors
      • Submit an article
      • Ethics in publishing
      • Editorial statute

    Subscribe to our newsletter

    Article options
    • Read in English
    • Download PDF
    • Bibliography
    Tools
    • Print
    • Send to a friend
    • Export reference
    • CrossMark
    • Mendeley
    • Statistics
    en pt

    Are you a health professional able to prescribe or dispense drugs?

    Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

    By checking that you are a health professional, you are stating that you are aware and accept that the Portuguese Journal of Cardiology (RPC) is the Data Controller that processes the personal information of users of its website, with its registered office at Campo Grande, n.º 28, 13.º, 1700-093 Lisbon, telephone 217 970 685 and 217 817 630, fax 217 931 095, and email revista@spc.pt. I declare for all purposes that the information provided herein is accurate and correct.